Literature DB >> 21163854

Personal benefit, or benefiting others? Deciding whether to take part in clinical trials.

Louise Locock1, Lorraine Smith.   

Abstract

BACKGROUND: Participation in clinical trials is critical for the success of evidence-based healthcare. Much previous research suggests that people take part in clinical trials mostly for altruistic reasons, and that deriving personal benefit is a secondary consideration.
PURPOSE: To investigate patients' reasons for deciding whether to take part in clinical trials and the extent to which personal benefit may be a motivating factor.
METHODS: A qualitative study utilizing in-depth semi-structured interviews. Participants were 42 men and women who had been asked to participate in clinical trials testing a range of interventions in different conditions, including some who did not participate or withdrew. Trials were based in either primary or secondary care. Interviews were conducted at home.
RESULTS: Reasons for taking part were complex and a wide variety of personal considerations were evident. Gaining some personal benefit emerged as an important primary motivation in this group of respondents, whereas altruistic considerations appeared to be largely subsidiary. People who decided not to take part were also mainly concerned about the balance of personal risk and benefit. LIMITATIONS: Public dissemination of the results may have influenced participants' responses.
CONCLUSIONS: Achieving target sample sizes for clinical trials may be enhanced by an understanding of what is likely to motivate patients to take part. In this study, respondents identified a range of attractive benefits, such as care in a specialist team with expert staff, active engagement in their health monitoring or care, more frequent or intensive monitoring, and information about the latest research into their condition.

Entities:  

Mesh:

Year:  2010        PMID: 21163854     DOI: 10.1177/1740774510392257

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  39 in total

1.  Reasons for non-participation in an international multicenter trial of a new drug for tuberculosis treatment.

Authors:  D Lamunu; K N Chapman; P Nsubuga; G Muzanyi; Y Mulumba; M A Mugerwa; S Goldberg; L Bozeman; M Engle; J Saukkonen; S Mastranunzio; H Mayanja-Kizza; J L Johnson
Journal:  Int J Tuberc Lung Dis       Date:  2012-04       Impact factor: 2.373

2.  Factors influencing enrollment of African Americans in the Look AHEAD trial.

Authors:  David L Mount; Cralen Davis; Betty Kennedy; Susan Raatz; Kathy Dotson; Tiffany L Gary-Webb; Sheikilya Thomas; Karen C Johnson; Mark A Espeland
Journal:  Clin Trials       Date:  2011-11-07       Impact factor: 2.486

3.  Randomized clinical trials as reflexive-interpretative process in patients with rheumatoid arthritis: a qualitative study.

Authors:  Mercedes de Jorge; Sonia Parra; Jenny de la Torre-Aboki; Gabriel Herrero-Beaumont
Journal:  Rheumatol Int       Date:  2015-01-31       Impact factor: 2.631

4.  Open urethroplasty versus endoscopic urethrotomy for recurrent urethral stricture in men: the OPEN RCT.

Authors:  Robert Pickard; Beatriz Goulao; Sonya Carnell; Jing Shen; Graeme MacLennan; John Norrie; Matt Breckons; Luke Vale; Paul Whybrow; Tim Rapley; Rebecca Forbes; Stephanie Currer; Mark Forrest; Jennifer Wilkinson; Elaine McColl; Daniela Andrich; Stewart Barclay; Jonathan Cook; Anthony Mundy; James N'Dow; Stephen Payne; Nick Watkin
Journal:  Health Technol Assess       Date:  2020-11       Impact factor: 4.014

5.  The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase I trials.

Authors:  Alexia Iasonos; Mrinal Gounder; David R Spriggs; John F Gerecitano; David M Hyman; Sarah Zohar; John O'Quigley
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

6.  Motivational assessment of non-treatment buprenorphine research participation in heroin dependent individuals.

Authors:  Gina Papke; Mark K Greenwald
Journal:  Drug Alcohol Depend       Date:  2011-12-02       Impact factor: 4.492

7.  Stakeholder views on participant selection for first-in-human trials in cancer nanomedicine.

Authors:  P Satalkar; B S Elger; D M Shaw
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

8.  Is there a role for physician involvement in introducing research to surrogate decision makers in the intensive care unit? (The Approach trial: a pilot mixed methods study).

Authors:  K E A Burns; L Rizvi; O M Smith; Y Lee; J Lee; M Wang; M Brown; M Parker; A Premji; D Leung; M Hammond Mobilio; L Gotlib-Conn; R Nisenbaum; M Santos; Y Li; S Mehta
Journal:  Intensive Care Med       Date:  2014-12-10       Impact factor: 17.440

9.  Artificial pancreas (AP) clinical trial participants' acceptance of future AP technology.

Authors:  Wendy C Bevier; Serena M Fuller; Ryan P Fuller; Richard R Rubin; Eyal Dassau; Francis J Doyle; Lois Jovanovič; Howard C Zisser
Journal:  Diabetes Technol Ther       Date:  2014-05-08       Impact factor: 6.118

10.  Drivers and barriers to patient participation in RCTs.

Authors:  V Jenkins; V Farewell; D Farewell; J Darmanin; J Wagstaff; C Langridge; L Fallowfield
Journal:  Br J Cancer       Date:  2013-03-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.